Alzheimers disease
Conditions
Interventions
Test Group:Cervical deep lymphatic/lymph node-venous anastomosis
Sponsors
The Second Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patient themselves or their guardian signs an informed consent form. 2. Age 50 to 75 years old (>=50 years, =10 points. 5. Positive findings on ß-amyloid PET imaging (>=37 centiloids). 6. Educational level of primary school graduation or above. 7. HAMD score is =grade 1, <=grade 3).
Exclusion criteria
Exclusion criteria: 1. Presence of contraindications for MRI, ICG angiography, or PET scan. 2. Presence of contraindications for lumbar puncture. 3. Severe cardiac disease or unstable hemodynamic status. 4. Severe pulmonary disease, including severe obstructive, restrictive, or mixed ventilatory dysfunction, or acute inflammation within the past 3 months. 5. Hepatic insufficiency, with AST or ALT > 3 times the upper limit of normal. 6. Renal insufficiency, with GFR =4 microbleeds within the cerebral lobes. 8. History of cerebral hemorrhage or cerebral infarction (excluding lacunar infarction). 9. Hematological diseases, coagulation disorders, or abnormal coagulation function. 10. Thyroid dysfunction. 11. Intracranial or cervical vascular lesions. 12. Uncontrolled severe hypertension, with systolic blood pressure >= 180 mmHg or diastolic blood pressure >= 110 mmHg. 13. Diseases requiring systemic steroid use. 14. Drug addiction (including addiction to psychotropic drugs, narcotics, and alcohol). 15. Severe infectious diseases, including HIV positivity and severe infections. 16. Severe mental disorders or potential suicide risk (NGASR score >= 9). 17. Within 3 years after radical surgery for malignant tumors. 18. Participation in other interventional clinical trials within the past three months. 19. Poor compliance as judged by the physician, unable to complete or unwilling to cooperate with regular follow-ups after surgery. 20. Other situations deemed by the physician as unsuitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuroimaging examination;MRI scan assessment of hippocampus and temporal lobe volume changes;PET scan assessment of ß-amyloid pathology(AV1,AV45)and Tau protein pathology(AV1451);Biofluid biomarker examination;Concentration level of cerebrospinal fluid P-tau181;Plasma P-tau181 concentration level;Cerebrospinal fluid Aß-42 concentration level;Plasma P-tau181 concentration level; | — |
Countries
China
Contacts
Public ContactLiu Jun
The Second Hospital of Jilin University
Outcome results
None listed